CytoMed Therapeutics Limited (NASDAQ:GDTC) Shares Shorted: Short Interest Up 372.4% in September

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 17,102 shares, a growth of 372.4% from the September 15th total of 3,620 shares. Based on an average daily volume of 15,986 shares, the short-interest ratio is presently 1.1 days. Currently, 0.1% of the company’s shares are sold short.

CytoMed Therapeutics Stock Down 8.8%

Shares of NASDAQ:GDTC traded down $0.08 during midday trading on Monday, reaching $0.81. 54,761 shares of the company’s stock were exchanged, compared to its average volume of 217,489. CytoMed Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $3.68. The firm’s 50 day simple moving average is $0.90 and its two-hundred day simple moving average is $0.98.

CytoMed Therapeutics (NASDAQ:GDTC) last posted its earnings results on Wednesday, September 30th. The company reported ($0.06) EPS for the quarter. The business had revenue of $0.06 million for the quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on GDTC. Fundamental Research set a $4.16 price target on shares of CytoMed Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CytoMed Therapeutics currently has an average rating of “Hold” and an average price target of $4.16.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research programs are designed to use immune cells to recognize and attack cancer cells, with an emphasis on potentially scalable, off-the-shelf treatments.

CytoMed’s technology platform includes the development of allogeneic cell therapies derived from healthy donors, including therapies based on gamma-delta T cells and other immune-cell types.